Akademiliv

Sahlgrenska akademins nyheter

På Svenska
University of Gothenburg Logotype
  • News
  • Notices
  • Grants
  • About Akademiliv
Each year about 1,600 people in Sweden are afflicted by pancreatic cancer. Now the Sjöberg Foundation is providing grants to two research projects at Sahlgrenska Academy, both of which can contribute to better treatments for this type of cancer. Photo from iStock photo agency.

Sjöberg Foundation gives SEK 9 million for cancer research at Sahlgrenska Academy

18 February, 2019

GRANTS. The Sjöberg Foundation recently decided to support two teams conducting cancer research at Sahlgrenska Academy with grants totaling SEK 9 million. A study that can pave the way for using immunotherapy as a treatment for pancreatic cancer received the largest grant.

Peter Naredi is the principal applicant for that project, which receives SEK 6 million from the Sjöberg Foundation. The translational project deals with improved diagnosis and treatment of patients with pancreatic cancer. Today most patients with advanced pancreatic cancer gain little or no benefit from medical cancer treatment. In the laboratory researchers hope to identify which therapy is most efficient killing the patient’s tumor, and then this knowledge will be transfered to patients. In case of recurrence, the  treatment option can then be administered to the patient in clinical studies. The second aim of the project is identifying tumor markers in blood from people with premalignant or early stages of pancreatic cancer.

Immune-stimulating treatment

Peter Naredi. Photo: Johan Wingborg.

“In the clinic we collect blood samples and tumor tissue in conjunction with surgical removal of tumors,” Peter Naredi says. “We use the blood samples to identify tumor markers. With the tumor tissue, we create what is known as a PDX biobank with mice carrying pancreatic cancer. We conduct genetic analyses of cancer cells and cultivate the cells for tests of new pharmaceutical substances. In mice with pancreatic cancer from different patients, we test their ability to respond to immune-stimulating treatment. These experiments enable us to plan for clinical studies of targeted cancer treatments to patients experiencing a relapse of their cancer.”

An opening for immunotherapy

Great progress has been made strengthening the body’s immune system against cancer cells, and several effective immunotherapy treatments are now helping patients. Immunotherapy has been thought to rarely or never work in the case of pancreatic cancer, but the research team at Sahlgrenska Academy and Sahlgrenska University Hospital has results indicating that more effective immunotherapy can be identified for this form of cancer as well.

“We have preliminary data from our experimental attempts indicating that patients’ own T cells can be effective against pancreatic tumors if they are stimulated in the right way. Being able to continue these studies and then start early clinical studies is both important and exciting,” says Peter Naredi.

The first major funding

Conducting the project requires collaboration of a team of researchers, and Naredi emphasise that the Sjöberg Foundation grant means a great deal. The Department of Surgery also includes researchers Lisa Nilsson, Johan Bourghardt Fagman, Cecilia Engström and Caroline Vilhav, and those participating from the Department of Oncology include Changyan Chen, Daniel Giglio and Lars Ny.

“Systematically collecting pancreatic cancer tissue in surgery and then cultivating it in a PDX model requires a lot of resources and the contributions of many people,” Naredi says. “The experiments and analyses we conduct come at a high cost, and the pharmaceuticals we will use in the clinical studies are very expensive. The Sjöberg Foundation’s funding is the first major grant we have received, and it can finance part of the project.”

Chemotherapy first

The project for which Svein Olav Bratlie is the principal applicant, receives SEK 3 million from the Sjöberg Foundation, and it also concerns pancreatic cancer. Based on an assessment in a multidisciplinary therapy conference, an estimated one out of three patients is a candidate for curative treatment. This often involves surgery to remove the tumors followed by supplementary chemotherapy. However, the surgery may result in complications that prevent patients from receiving the planned chemotherapy, and more than 15 to 20 percent of patients undergoing surgery suffer a recurrence within a year.

The project, Nordic Pancreatic Cancer Trial (NorPACT-1), is an international multicenter controlled clinical study. In the study researchers evaluate whether chemotherapy administered before surgery results in less patients with an early recurrence. Through random selection, patients will either receive chemotherapy and then surgery or surgery first.

Svein-Olav Bratlie

“We believe that the strategy of administering chemotherapy before surgery results in more patients receiving the combination treatment and that preliminary treatment with chemotherapy eliminates possible micrometastases, which in itself would reduce the risk of early recurrence of the disease,” Bratlie says.

“In NorPACT-1 we study whether we are seeing a better survival rate if we administer chemotherapy before, instead of after, surgery. The generous grant from the Sjöberg Foundation will help us to implement the Swedish part of this important and sought-after study.”

Future customized treatment

This study also provides unique access to a patient base that makes it possible to study blood and tumor tissue.

“With the grant from the Sjöberg Foundation, we can now, through our established network and through translational research, obtain answers to questions about which factors in the tumor are affected by the administered chemotherapy. In experimental models and in cell culture, we can try to produce unique tumor expressions that can then lead us on the path towards an oncological treatment system tailored for the unique patient afflicted with cancer.”

TEXT: ELIN LINDSTRÖM CLAESSEN

By: Elin Lindström
Tagged With: Bidrag och stipendier, cancer, Cancerforskning

HAPPY SUMMER!

The newsletter from Akademiliv will return on Wednesday, August 21st.

Contact your institute to add your event to the calendar in the Staff Portal

  • Biomedicine: Kristian Kvint: kalender@biomedicine.gu.se
  • Core Facilities: Amelie Karlsson: amelie.karlsson.2@gu.se
  • Clinical Sciences: Katarina Olinder Eriksson: klinvet@gu.se
  • Medicine: Nina Raun; kommunikation@medicine.gu.se
  • Neuroscience and Physiology: Josefin Bergenholtz; kommunikation@neuro.gu.se
  • Odontology: Johan Thompson; info@odontologi.gu.se
  • Sahlgrenska Academy’s Office and faculty-wide calendar events Åsa Ekvall; info@sahlgrenska.gu.se
  • Health and Care Sciences: Karin Mossberg; vardvetenskap@fhs.gu.se

Information from Sahlgrenska Academy Research Support Office

[UPDATED JUNE 2024]
The Sahlgrenska Academy Research Support Office provides an overview of upcoming and current calls, nominations and events in an information letter. This letter is updated on a monthly basis.
Current and previous newsletters are also available in the Staff Portal.

’20 minutes for researchers’ is back – see full spring program

During 20 minutes over Zoom, the Biomedical Library gives tips on tools and services that can facilitate your research everyday life.

More news

En personlig död (A Personal Death) – a chance to win Björn Fagerberg’s new book

27 May, 2024

NEW BOOK. During his career as a physician specializing in internal medicine, Björn Fagerberg has been involved in many end-of-life situations, …  

She is doing her residency in the US with a medical degree from Gothenburg

21 May, 2024

STUDENT. Doing a “residency” in orthopedics in the United States is an unattainable dream for many newly qualified American doctors. Now Janina Ka …  

Alba Corell reports from a high-level brain tumor meeting

20 May, 2024

COLUMN. The recent gathering of the Scandinavian Society of Neuro-oncology (SNOG) in Gothenburg has concluded. Professor Asgeir Jakola hosted and …  

From South Africa to Sweden: Collaborative Research Efforts Improving Pregnant Women’s Health

17 May, 2024

GLOBAL HEALTH. In the bustling Tygerberg University Hospital in Cape Town, a dedicated research team led by Lina Bergman, is on a mission to …  

Sara Bjursten and Anna Wenger are the recipients of the Assar Gabrielsson Prize 2024

17 May, 2024

AWARD. The Assar Gabrielsson Foundation has named Anna Wenger as the winner in the basic science research category and Sara Bjursten as the …  

A full day for PhD students focused on mental health

16 May, 2024

PHD STUDENTS. For the sixth time, PhD students at Sahlgrenska Academy were invited to PhD Day, organized by the Doctoral Student Council. The day …  

Kaj Blennow ranked highest in Sweden in neuroscience

16 May, 2024

AWARD. In this year's edition of the researcher ranking from Research.com in the field of neuroscience, Kaj Blennow is ranked 17th …  

Linda Wass is doing a postdoc at Stanford with ALF funding

14 May, 2024

ALF FUNDING. Biomedical Scientist Linda Wass has just settled in Stanford, California, where she will spend two years as a postdoc. She is the …  

Karin Nilsson wrote the Thesis of the Year at Sahlgrenska Academy in 2023

14 May, 2024

AWARD. Karin Nilsson, currently a postdoc at the Department of Internal Medicine and Clinical Nutrition, receives the faculty-wide Thesis of the …  

Some answers from the proposed members of the next Faculty Board

14 May, 2024

FACULTY ELECTIONS. The eight proposed members of the next Faculty Board hereby give some brief answers on how they want to contribute to the work …  

More news...

Sahlgrenska Academy

© University of Gothenburg
PO-Box 100, S-405 30 Gothenburg, Sweden
Phone: 00 46 31 786 0000

About the website

Elin Lindström is editor for Akademiliv.
Please feel free to send your ideas and comments to akademiliv@gu.se

Sign up for the Akademiliv newsletter:

Send you tips to Akademiliv

Do you have a suggestion for news, grants, seminars or an education?
Send an email to Elin Lindström Claessen